Scleroderma

Assessment of Life Expectancy in Scleroderma-Associated Pulmonary Arterial Hypertension

Assessment of Life Expectancy in Scleroderma-Associated Pulmonary Arterial Hypertension

By

Patients with scleroderma-associated isolated pulmonary arterial hypertension (SSc-PAH) have a slightly higher mortality risk than patients SSc-PAH with concomitant interstitial lung disease.

Pulmonary Arterial Hypertension in Systemic Sclerosis: Swift Diagnosis and Effective Treatment

Pulmonary Arterial Hypertension in Systemic Sclerosis: Swift Diagnosis and Effective Treatment

By

Rheumatology specialists should be aware of the clinical features of SSc-PAH, as well as the tools available to facilitate a prompt, accurate diagnosis.

Key Hemodynamic Differences Noted With Scleroderma-Associated PAH vs Idiopathic PAH

Key Hemodynamic Differences Noted With Scleroderma-Associated PAH vs Idiopathic PAH

By

Patients with systemic sclerosis-associated pulmonary arterial hypertension display important differences in hemodynamic and pulmonary function parameters compared with patients with idiopathic PAH.

Systemic Sclerosis: Capillaroscopic and Ultrasonographic Evaluations

Systemic Sclerosis: Capillaroscopic and Ultrasonographic Evaluations

By

Microvascular damage evaluated using nailfold capillaroscopy and macrovascular features that include ulnar artery occlusion, assessed per hand power Doppler ultrasonography, have demonstrated associations with the main digital manifestations of systemic sclerosis.

Systematic Sclerosis Ulcers Benefit from Hyperbaric Oxygen Treatment

Systematic Sclerosis Ulcers Benefit from Hyperbaric Oxygen Treatment

By

Hyperbaric oxygen therapy completely healed 4 patient's systemic sclerosis ulcers.

Systemic Sclerosis Linked to Occupational Heavy Metal Exposure

Systemic Sclerosis Linked to Occupational Heavy Metal Exposure

By

Median levels of 24 elements were assessed in patients with systemic sclerosis and matched controls.

Immunosuppressants Effective for Early Diffuse Cutaneous Systemic Sclerosis Treatment

Immunosuppressants Effective for Early Diffuse Cutaneous Systemic Sclerosis Treatment

By

Prospective, observational study assessed 4 treatment protocols and their effects on skin thickening.

Raynaud Phenomenon: Revisiting a Cold Weather Problem

Raynaud Phenomenon: Revisiting a Cold Weather Problem

A thorough work-up can differentiate between primary and secondary forms, mitigating progression of a more severe underlying disease.

Efficacy of Open-Label Tocilizumab in Early Systemic Sclerosis

Efficacy of Open-Label Tocilizumab in Early Systemic Sclerosis

By

Dinesh Khanna, MD, MSc, discusses results of the open-label portion of a trial evaluating the safety and efficacy of placebo-treated patients with systemic sclerosis who were switched to received open-label tocilizumab.

Emerging Research in Pediatric Localized Scleroderma

Emerging Research in Pediatric Localized Scleroderma

By

Sarah Taber, MD, briefly reviews her ongoing research on genetic drivers of localized scleroderma in pediatric patients.

Predictors of Gangrene in Patients With SSc and Digital Ulcers

Predictors of Gangrene in Patients With SSc and Digital Ulcers

By

Researchers sought to clarify the rates and risk factors of gangrene formation in patients with SSc utilizing the Digital Ulcer Outcomes Registry.

Decreasing Morbidity Associated With Scleroderma By Addressing Pain Management

Decreasing Morbidity Associated With Scleroderma By Addressing Pain Management

By

As part of Scleroderma Awareness Month, physicians specializing in the management of scleroderma discuss mitigating effects of scleroderma-related pain and improving quality of life for their patients.

Ischemic Digital Ulcers Not Reduced by Endothelin-1 Blocker Macitentan in SSc

Ischemic Digital Ulcers Not Reduced by Endothelin-1 Blocker Macitentan in SSc

Treatment with the endothelin-1 blocker macitentan did not reduce the incidence of new digital ulcers over 16 weeks.

Emerging Novel Treatment Strategies for Raynaud Phenomenon

Emerging Novel Treatment Strategies for Raynaud Phenomenon

By

If conservative treatment with medications such as dihydropyridine, calcium channel blockers, alpha-adrenergic blockers, and phosphodiesterase-5 inhibitors is unsuccessful, clinicians can consider chemical sympathectomy, botulinum neurotoxin injection, and fat pad grafting.

Predictors of Skin Fibrosis Regression in Diffuse Cutaneous Systemic Sclerosis

Predictors of Skin Fibrosis Regression in Diffuse Cutaneous Systemic Sclerosis

By

Regression of skin fibrosis is a feature of the natural history of dcSSc. However, the pattern of regression can be quite heterogeneous despite improvements in predicting progression.

Case Study and Clinical Highlight:  Diagnosis of Pulmonary Involvement in Systemic Sclerosis

Case Study and Clinical Highlight: Diagnosis of Pulmonary Involvement in Systemic Sclerosis

By

Engage in this case study to test your diagnostic ability to differentiate pulmonary hypertension in the setting of systemic sclerosis.

Increased Risk of Venous Thromboembolism in Systemic Sclerosis

Increased Risk of Venous Thromboembolism in Systemic Sclerosis

By

Patients with systemic sclerosis may have an increased risk of VTE in the first year following diagnosis.

Promising Treatment for Scleroderma-Related Interstitial Lung Disease

Promising Treatment for Scleroderma-Related Interstitial Lung Disease

By

Cyclophosphamide and mycophenolate mofetil efficacious for scleroderma-related lung disease, according to trial data reported at ACR/ARHP 2015.

Sign Up for Free e-newsletters